A Prospective, Multicenter Atherectomy Study Showing Luminal Gain in Subjects With Peripheral Vascular Blockages
Study Details
Study Description
Brief Summary
To evaluate the safety and effectiveness of the DABRA Laser System in the atherectomy of peripheral vascular stenoses.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Excimer Laser Photoablation Device: DABRA Laser System Patients with symptomatic peripheral vascular disease undergoing an endovascular revascularization procedure utilizing the DABRA Laser System. |
Device: Atherectomy
Endovascular treatment of peripheral arterial disease
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Technical Success [At Index Procedure]
The Primary Efficacy Endpoint is the mean reduction in percent diameter stenosis in each subject's primary lesion following treatment with the DABRA Laser System and before any other treatment, as assessed by an independent Angiographic Core Laboratory.
- Freedom from Major Adverse Events (MAE) [30 Days]
Primary safety endpoint is freedom from Major Adverse Events, defined as all-cause mortality, unplanned major target limb amputation (at or above the ankle), clinically driven target limb revascularization (CD-TLR) at 30 Days, as classified by the Clinical Events Committee (CEC).
Secondary Outcome Measures
- Incidence of Target Lesion Revascularization (TLR) at 6 months [6 months]
Clinically driven target lesion revascularization (TLR) at 6 months.
- Reduction in Residual Diameter Stenosis [At Index Procedure]
Incidence of achieving a residual diameter percent stenosis of ≤ 50% in the primary lesion on the day of treatment, prior to any adjunctive therapy.
- Rutherford Classification [30 Days, 6 Months]
Change from baseline in Rutherford Category.
- Change in Percent Diameter Stenosis [30 Days, 6 Months]
Percent diameter stenosis and change from baseline in percent diameter stenosis as measured by Doppler Ultrasound and assessed by an independent core laboratory.
- Vessel Patency [30 Days, 6 Months]
Vessel patency as measured by Doppler ultrasound and assessed by an independent core laboratory.
Eligibility Criteria
Criteria
Participants must meet all of the inclusion criteria to participate in this study:
Inclusion Criteria
-
Ability and willingness to give written informed consent and comply with follow-up requirements
-
PAD with Rutherford Class 2-5
-
Stenotic lesion(s) in the peripheral vasculature
-
Subject is a candidate for atherectomy for infrainguinal peripheral artery disease
Angiographic Inclusion Criteria
-
Target vessel with documented stenosis by angiography ≥70% and ≤100% by angiography (as determined by Investigator)
-
Target vessel ≤ 3.0 mm in diameter
-
Target Lesion ≤ 25cm in length
-
The lesion to be treated is not severely calcified
-
Untreated ipsilateral iliac stenosis ≤70% (or tortuosity that might prevent advancing sheath to lesion) as applicable depending on access
-
No use of another atherectomy device in the same procedure
-
Treatment site is not located in a graft
-
Treatment site is not in, or distal to, a previously placed stent
-
No flow limiting dissection proximal, distal, or in the target lesion (prior to the use of the investigational device)
Participants meeting any of the exclusion criteria at the time of enrollment (index procedure/ intervention) will be excluded from study participation:
Exclusion Criteria
-
Age below 22 years
-
Pregnant, breastfeeding, planning to become pregnant. If women of reproductive capability will be enrolled, status will be assessed via pregnancy testing. Subject must agree to use effective birth control measures for duration of study. Pregnancy during study must be reported immediately.
-
Myocardial infarction (MI) ≤ 60 days prior to procedure
-
Cerebrovascular Accident (CVA) ≤ 60 days prior to procedure
-
Endovascular or surgical procedure ≤ 30 Days prior to procedure or a planned endovascular or surgical procedure within 30 days after the index procedure
-
Disorders or allergies precluding use of radiographic contrast including renal insufficiency severe enough to contraindicate use of radiographic contrast
-
Subjects in whom anti-platelet, anticoagulant, or thrombolytic therapy is contraindicated
-
Life expectancy ≤ 12 months
-
Patient is participating in another investigational drug or device study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | California Heart & Vascular Clinic | El Centro | California | United States | 92243 |
| 2 | Merced Vein & Vascular Center | Merced | California | United States | 95340 |
| 3 | The Cardiac & Vascular Institute | Gainesville | Florida | United States | 32605 |
| 4 | Vascardio Heart and Vascular Institute | Hialeah | Florida | United States | 33013 |
| 5 | MIMIT Health | Chicago | Illinois | United States | 60616 |
| 6 | MIMIT Health | Glen Ellyn | Illinois | United States | 60137 |
| 7 | Eastlake Cardiovascular | Roseville | Michigan | United States | 48066 |
| 8 | South Texas Vascular Institute | Edinburg | Texas | United States | 78539 |
| 9 | Texas Tech University Health Sciences Center - Center for Cardiovascular Health | Lubbock | Texas | United States | 79430 |
| 10 | Laser Surgical Solutions | McAllen | Texas | United States | 78501 |
Sponsors and Collaborators
- Ra Medical Systems
Investigators
- Study Chair: Athar Ansari, MD,
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RMS 103